Vivian Jiang

8PUBLICATIONS
23CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Cheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 23, 2025
TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma.

Wei Wang, Qingsong Cai, Yang Liu

|Jul 21, 2025
YX0798 is a highly potent, selective, and orally effective CDK9 inhibitor for treating aggressive lymphoma.

Vivian Jiang, Yu Xue, Hong Kim

|Mar 30, 2022
Dual targeting of PI3K and BCL-2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma.

Haige Ye, Shengjian Huang, Yang Liu

|May 18, 2021
Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.

Shaojun Zhang, Vivian Changying Jiang, Guangchun Han

|Oct 27, 2018
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.

Hui Guo, Dongfeng Zeng, Hui Zhang

|Jan 24, 2017
JNK1 negatively controls antifungal innate immunity by suppressing CD23 expression.

Xueqiang Zhao, Yahui Guo, Changying Jiang

Pageof 2

Frequent Collaborators

6 joint publications

Michael Wang

3 joint publications

Chi Young Ok

2 joint publications

Shaojun Zhang

2 joint publications

Guangchun Han